Trilaciclib Approved for Chemo-Induced Myelosuppression in Small-Cell Lung Cancer

The FDA has approved trilaciclib (CoselaTM, G1 Therapeutics) for the prevention of myelosuppression in patients receiving chemotherapy for extensive-stage small-cell lung cancer (SCLC). Occurring when chemotherapy agents damage the bone marrow, myelosuppression decreases the production of red blood cells, white blood cells, and platelets, causing patients to experience fatigue, bleeding, and increased risk of infection. "Chemotherapy is a mainstay of cancer treatment; however, its side effects, ...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts